biobide

FEBRUARY 2, 2024

Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies. This is why not many Pharma companies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

KIF1A

APRIL 6, 2024

Read the Article Rare Roundup Columbia Receives $15M for Ultra-Rare ALS Medicines Creation Gene-based therapies like Antisense Oligonucleotides have taken major strides in recent years, including Susannah Rosen’s current n-of-1 ASO trial. She graduated from UC San Diego with a B.S. degree in human biology in 2023.

DNA 111

DNA Medical Schools Therapies Research 111

Drug Target Review

SEPTEMBER 14, 2023

Dr Cristina Ureche from Hannover Medical School (MHH) guides us through the aseptic process of viral vector-based vaccines, and Dr Mark J. Dr Brian Kaspar of Insmed Incorporated guides us from bench to bedside, addressing key challenges in gene therapy. Newman of GeoVax, Inc.,

Vaccine 105

Vaccine Medical Schools Drugs Therapies 105

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both of the new gene therapy studies were published online Dec. SATURDAY, Dec. 5 in the New England Journal of Medicine.

Therapies 52

Therapies Disease Medical Schools Virus 52

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs. The study appears in Nature Biotechnology.

RNA 98

RNA Medical Schools Engineering DNA 98

Broad Institute

NOVEMBER 21, 2024

Bernstein is also chair of the Department of Cancer Biology at Dana-Farber Cancer Institute, a professor in cell biology and pathology at Harvard Medical School, and holds the Richard and Nancy Lubin Family Chair. Improving therapy Moreover, the researchers discovered a new effect of the excessive methylation.

52

52

Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. However, if the therapy targets only the subclonal (branch) mutations, this will result in the mere ‘pruning’ of specific branches rather than elimination of the whole cancer.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Drug Target Review

FEBRUARY 29, 2024

Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapy drug development. AskBio) I continue to work to bring innovative gene therapies to patients in need. In my current role at Asklepios BioPharmaceutical, Inc.

Therapies 111

Therapies Disease Clinical Trials Science 111

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

Broad Institute

MARCH 8, 2024

It is currently not fully understood why a given person develops the disease or why there is a lot of variation around clinical features across people with the disease,” said senior author Miriam Udler, director of the MGH Diabetes Genetics Clinic, an assistant professor of medicine at Harvard Medical School, and an associate member at Broad.

Medical Schools 127

Medical Schools Hospitals Disease Therapies 127

Broad Institute

FEBRUARY 7, 2024

It examined endothelial mechanisms unrelated to lipid metabolism (a known driver of CAD risk with effective therapies, like statins) in hopes of uncovering other mechanisms driving CAD risk for which therapies may yet be developed. “Now

Disease 105

Disease Hospitals Medical Schools Therapies 105

Broad Institute

AUGUST 19, 2024

This study is an important example of how understanding core metabolic requirements and functions of key bacteria can lead directly to new therapies that allow us to modify the microbiome for improved health,” said co-senior author Seth Bloom, an infectious diseases instructor at the Massachusetts General Hospital.

Hospitals 121

Hospitals Treatment Medical Schools Science 121

The Pharma Data

JUNE 2, 2023

Zouboulis, President of the European Hidradenitis Suppurativa Foundation, Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany.

Medical Schools 52

Medical Schools Treatment Disease Therapies 52

Broad Institute

NOVEMBER 13, 2023

Doing so would guide treatment decisions, such as whether to continue therapy. "We Such a test could help physicians detect recurrences earlier, intervene sooner, and tailor therapy to each patient. Earlier this year, the Broad entered into an agreement with Exact Sciences to further develop the MAESTRO MRD test for clinical use.

DNA 116

DNA Medical Schools Treatment Therapies 116

Nvidia Developer: Drug Discovery

JULY 14, 2022

Drug discovery startup Insilico Medicine—alongside researchers from Harvard Medical School, Johns Hopkins School of Medicine, the Mayo Clinic, and. The five existing FDA-approved therapies for the disease are unable to halt or reverse this loss of function, which affects more than 700,000 people around the world. “The

Medical Schools 52

Medical Schools Clinical Trials Engineering FDA Approval 52

Broad Institute

APRIL 2, 2024

He is also a professor at Harvard Medical School and Massachusetts General Hospital. But scientists haven’t been able to target those connections with therapies in part because they lack a complete understanding of metabolic pathways in the gut.

Disease 145

Disease Medical Schools Hospitals DNA 145

The Pharma Data

SEPTEMBER 18, 2020

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi and Regeneron’s jointly-developed PD-1 inhibitor Libtayo (cemiplimab) in the treatment of locally advanced basal cell carcinoma (BCC) in patients for whom hedgehog inhibitor (HHI) therapy is not applicable.

Medical Schools 52

Medical Schools Trials Therapies Hospitals 52

Broad Institute

JUNE 1, 2023

The work was co-led by senior author Pradeep Natarajan , an associate member at the Broad, the director of preventive cardiology at Massachusetts General Hospital, and an assistant professor of medicine at Harvard Medical School. Maternal meta-analysis Scientists have long thought that HDPs are caused in part by genetics.

Doctors 133

Doctors Medical Schools Hospitals DNA 133

Drug Target Review

JUNE 6, 2023

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. For the last several years, the field has worked to unlock the potential of IO therapies for additional tumour types, and has explored options beyond checkpoint inhibitors.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

MAY 16, 2024

1,2 The application of endogenous compounds is a highly pragmatic approach for the creation of disease-modifying therapies. Currently, gene therapy is being developed to correct inborn errors of metabolism, primary immune-deficiencies, and other types of diseases where the genetic lesion is defined. Front Endocrinol (Lausanne).

Disease 64

Disease Therapies Medical Schools Treatment 64

Drug Target Review

JULY 1, 2024

Could you elaborate on the potential market size for SRP-001 and how it fits into the broader landscape of pain therapies? With a strong market entry strategy and continuous evidence generation, SRP-001 has the potential to transform pain therapy and meet the enormous unmet needs in this field. South Rampart Pharma, Inc.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Broad Institute

JANUARY 25, 2024

“We’ve come to realize recently that there is a lot more information that we can get from our retina images than we thought was possible,” says senior author Nazlee Zebardast, director of glaucoma imaging at Mass Eye and Ear and an assistant professor of ophthalmology at Harvard Medical School.

Disease 124

Disease Research Science Medical Schools 124

The Pharma Data

JUNE 7, 2023

These longer-term results show the durable overall survival benefit of sacituzumab govitecan over traditional chemotherapy in pre-treated HR+/HER2- metastatic breast cancer,” said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School. “At

Medical Schools 40

Medical Schools Therapies Treatment Clinical Development 40

The Pharma Data

NOVEMBER 10, 2020

from Harvard Medical School in Boston, and colleagues developed machine learning models to predict antibiotic susceptibility using electronic health record data and built a decision algorithm for recommending the narrowest possible antibiotic to which a specimen is susceptible for the treatment of uncomplicated UTI. TUESDAY, Nov.

Medical Schools 52

Medical Schools Science Therapies Trials 52

Drug Target Review

JANUARY 15, 2024

About the author Daniel Kavanagh, PhD, RAC Senior Scientific Advisor, Gene Therapies, Vaccines and Biologics at WCG Dr Kavanagh engages with sponsors, CROs and research institutions on topics related to human gene transfer research. Engineering soluble T-cell receptors for therapy. Cancer Therapy With TCR‑Engineered T Cells.

Engineering 110

Engineering DNA Virus Immune Response 110

Broad Institute

JULY 26, 2022

By Stephanie Dutchen, Harvard Medical School Office of Communications and External Relations July 26, 2022 Credit: Susanna Hamilton, Broad Communications From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. Study after study had suggested that A.

Research 52

Research Immune Response Medical Schools Disease 52

The Pharma Data

JANUARY 17, 2021

Ophthalmologists are physicians who have completed four years of medical school and four years of residency training. Treatments they help administer include patching therapy, prisms and convergence exercises. Danielle Natale, an optometrist at the Krieger Eye Institute in Baltimore, said in an institute news release.

Medical Schools 52

Medical Schools Doctors Treatment Disease 52

Drug Target Review

MARCH 15, 2024

He has a post-doctorate in virology, viral pathogenesis, viral vector development, and vaccines evaluation from Harvard Medical School, and a PhD in virology/molecular biology. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. References Mistry RK, Kelsall E, Sou SN, et al. Biotechnol Prog. Epub 2017 Sep 7.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

The Pharma Data

APRIL 22, 2023

It also explains why some patients do not respond as well as others to anti-PD1 therapy. We know we need an increased arsenal of weapons to use against cancer and have to put it together to improve treatment outcomes,” said Professor Iyer, who is also head of the Division of Medical Sciences at NCCS. Source link: [link]

Medical Schools 40

Medical Schools Therapies Treatment Hospitals 40

Broad Institute

JUNE 21, 2023

said Vamsi Mootha , senior author of the study, an institute member at the Broad, professor of systems biology and medicine at Harvard Medical School, and professor of molecular biology at Massachusetts General Hospital. Even with profound ataxia, these mice can still, under the correct therapeutic regimen, reverse course.”

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Broad Institute

OCTOBER 23, 2024

The work highlights the importance of examining the often-ignored noncoding parts of the genome when diagnosing rare genetic disorders, and also points to possible future genetic therapies that fine-tune CHASERR abundance as a means to treat CHASERR - and CHD2 -related disorders.

DNA 128

DNA RNA Disease Hospitals 128

The Pharma Data

DECEMBER 13, 2020

Their extensive experience and proven track record in advancing innovative therapies, in addition to strong leadership skills, will help us to strengthen our portfolio and accelerate technology translation to help patients in need.”. Dr. Zhang completed his postdoctoral fellowship at Harvard Medical School/Boston Children’s Hospital.

Medical Schools 40

Medical Schools Clinical Development Therapies RNA 40

Broad Institute

OCTOBER 4, 2023

The molecule’s dual mechanism of action — targeting both tumor and immune cells — is unique compared to other cancer immunotherapies including PD-1 drugs, and the researchers think it could explain why the molecule was so effective on its own in animal models and may not even need to be used in combination with other drugs such as anti-PD-1 therapy.

Small Molecule 128

Small Molecule Clinical Trials Engineering Trials 128

The Pharma Data

JANUARY 27, 2021

Yet insurance does not cover the therapy for stroke patients. That’s partly because after a stroke, the emphasis is often on rehab for any disabilities a patient might have, said Elizabeth Regan, a clinical assistant professor of physical therapy at the University of South Carolina, in Columbia. 27, 2021, online.

Medical Schools 52

Medical Schools Therapies Hospitals Doctors 52

On Medicine

APRIL 6, 2023

I have a background in Biomedical Engineering prior to medical school and a particular interest in global health and healthcare in resource-limited settings. I serve as a Professor of Pediatrics, Sidney Kimmel Medical School at Thomas Jefferson University and have been involved in medical education and research mentorship.

Medical Schools 52

Medical Schools Hospitals Treatment International 52

The Pharma Data

JANUARY 26, 2021

Dr. Short brings to VarmX extensive clinical development expertise, with a particular focus on rare diseases and gene therapy for haematological disorders. Short joins VarmX from Freeline Therapeutics, where he served for five years as SVP Clinical and Regulatory and later SVP Medical Science.

Clinical Development 40

Clinical Development Medical Schools Therapies Pharmaceuticals 40

The Pharma Data

MAY 15, 2023

Until bulevirtide, we have not had any approved options to treat these patients, but we now have a treatment conditionally approved specifically for HDV with a positive recommendation for full approval,” said Heiner Wedemeyer, MD, Director, Clinic for Gastroenterology, Hepatology and Endocrinology at Hannover Medical School. “It

Virus 40

Virus Marketing Treatment Science 40